Author

Neha Niranjan

Sanford Burnham Prebys Medical Discovery Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Akshata Udyavar· 1 shared Alexandra Stevens· 1 shared Amy Carr· 1 shared Anagha Deshpande· 1 shared Andrew R. NageriD· 1 shared Aniruddha J. DeshpandeiD· 1 shared Benjamin A. Garcia· 1 shared Cho-Ying ChiangiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Akshata Udyavar

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Disrupting a Convergent Acetylation Circuit Collapses Leukemic Identity Across AML Subtypes

Anagha Deshpande, Cho-Ying Chiang, Marlenne Perales, Neha Niranjan, Neelam Sinha, Darren Finlay, Alexandra Stevens, Emily Zahn, Benjamin A. Garcia, Irmela Jeremias, Mark Wunderlich, Kristen Jensen-Pergakes, Akshata Udyavar, Amy Carr, Andrew R. Nager, , Aniruddha J. Deshpande

This paper identifies an acetylation-dependent circuit controlling SEC integrity in AML, showing that disrupting KAT2A/B leads to broad anti-leukemic effects across subtypes.

bioRxiv · Jul 14, 2026 · PreprintCancer Biology